Amikacin is considered to be a major drug used for the treatment of *Mycobacterium avium* complex (MAC) disease, especially for patients who have cavitary disease or whose isolate is macrolide resistant (1–3). Its use is difficult in part because standard laboratory guidelines for susceptibility testing have not been established. The American Thoracic Society (ATS) and the 2011 Clinical and Laboratory Standards Institute (CLSI) guidelines currently recommend reporting primary susceptibilities only for clarithromycin and secondarily for linezolid and moxifloxacin against isolates of the MAC (1, 4).

In vitro and in a murine model, the bactericidal and chemotherapeutic efficacies of amikacin and other aminoglycosides against MAC have been known for >20 years; however, drug toxicities and adverse events, including hearing loss, have limited the chemotherapeutic use of intravenous (i.v.) or intramuscular (i.m.) amikacin, especially in elderly patients (1, 5, 6). The introduction of aerosolized amikacin has offered a potentially effective, practical, and less toxic alternative to parenteral administration of the antibiotic (7). The aerosolized form of amikacin has been touted as safer and easier to tolerate than the parenterally administered form. Additionally, it may be possible with the parenteral form to use a higher and thus presumably more effective dose than is usually tolerable with the i.v. or i.m. modalities (7). This formulation is being increasingly used in patients with MAC and with *Mycobacterium abscessus* infections.

We initiated a retrospective study of the *in vitro* MICs of amikacin in 462 consecutive isolates of the MAC submitted for susceptibility testing to the Mycobacteria/Nocardia Laboratory at UT Health Northeast (formerly The University of Texas Health Science Center at Tyler). The aim of our study was 2-fold. We retrospectively examined the *in vitro* MICs of amikacin in 462 consecutive isolates of the MAC that were submitted to our laboratory for susceptibility testing to determine a resistance breakpoint. Additionally, prior amikacin use was examined for patients with initial and repeat amikacin MICs of >64 μg/ml and those with an rrr gene mutation to help establish guidelines for an additional primary drug for treating MAC disease.

**MATERIALS AND METHODS**

**Organisms.** We studied 462 consecutive clinical isolates of the MAC that had been submitted for susceptibility testing to the Mycobacteria/Nocardia Research Laboratory at UT Health Northeast between 2011 and 2012. This laboratory receives isolates for susceptibility testing from all over the United States. Isolates were submitted as being of the MAC, most of which had been identified as MAC by a commercial probe assay, which according to the package insert has a sensitivity of 99.9% and specificity of 100%; however, the manufacturer states that rare isolates of MAC may not test positive by the probe assay. Isolates with initial and repeat amikacin MICs of >64 μg/ml were identified as species of the MAC by molecular identification using multiplex PCR and internal transcribed spacer (ITS) sequencing as previously described (8, 9).

Received 20 June 2013 Returned for modification 13 July 2013 Accepted 2 August 2013 Published ahead of print 14 August 2013

Address correspondence to Barbara A. Brown-Elliott, barbara.elliott@uthct.edu.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Amikacin against Isolates of *Mycobacterium avium* Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates

Barbara A. Brown-Elliott, a Elena Iakhieva, a David E. Griffith, b Gail L. Woods, c Jason E. Stout, d Cameron R. Wolfe, d Christine Y. Turenne, e Richard J. Wallace, Jr. a,b

Mycobacteria/Nocardia Research Laboratory and the Department of Microbiology, UT Health Northeast (formerly The University of Texas Health Science Center at Tyler) Tyler, Texas, USA; Department of Medicine, UT Health Northeast, Tyler, Texas, USA; Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA; Duke University Medical Center, Durham, North Carolina, USA; Saskatchewan Disease Control Laboratory, Regina, Saskatchewan, Canada.

Amikacin is a major drug used for the treatment of *Mycobacterium avium* complex (MAC) disease, but standard laboratory guidelines for susceptibility testing are not available. This study presents *in vitro* amikacin MICs for 462 consecutive clinical isolates of the MAC using a broth microdilution assay. Approximately 50% of isolates had amikacin MICs of 8 μg/ml, and 86% had MICs of ≤16 μg/ml. Of the eight isolates (1.7%) with MICs of 64 μg/ml, five had an MIC of 32 μg/ml on repeat testing. Ten isolates (2.1%) had an initial amikacin MIC of >64 μg/ml, of which seven (1.5%) had MICs of >64 μg/ml on repeat testing. These seven isolates had a 16S rRNA gene A1408G mutation and included *M. avium*, *Mycobacterium intracellulare*, and *Mycobacterium chimaera*. Clinical data were available for five of these seven isolates, all of which had received prolonged (>6 months) prior therapy, with four that were known to be treated with amikacin. The 16S mutation was not detected in isolates with MICs of ≤64 μg/ml. We recommend primary testing of amikacin against isolates of the MAC and propose MIC guidelines for breakpoints that are identical to the CLSI guidelines for *Mycobacterium abscessus*: ≤16 μg/ml for susceptible, 32 μg/ml for intermediate, and ≥64 μg/ml for resistant. If considered and approved by the CLSI, this will be only the second drug recommended for primary susceptibility testing against the MAC and should facilitate its use for both intravenous and inhaled drug therapies.
For isolates with MICs of ≥64 μg/ml, stored culture samples were screened for additional isolates recovered before or after the ≥64 μg/ml isolate.

**Susceptibility testing.** Antimicrobial susceptibility testing was performed using the CLSI-recommended method of broth microdilution in cation-adjusted Mueller-Hinton broth plus oleic acid-albumin-dextrose-catalase (OADC) using commercially available MIC panels (Thermo Fisher,formerly Trek Diagnostics, Cleveland, OH). Transparent colonies of the MAC (if present) were selected from Middlebrook 7H10 agar plates. The colonies were inoculated into cation-adjusted Mueller-Hinton broth plus 5% OADC. The inoculum was standardized to match a 0.5 McFarland standard by using a nephelometer. Serial dilutions were performed to deliver final concentrations of approximately 1 × 10^3 to 5 × 10^7 CFU/ml in a 0.1-ml volume. Susceptibilities were read using a mirrored light box (Trek Diagnostics) after incubation at 35°C in room air for 7 days. The endpoint (MIC) was complete inhibition of growth. Concentrations of amikacin tested ranged from 128 to 64 μg/ml. For isolates with MICs of >64 μg/ml, stored culture samples were screened for additional isolates recovered before or after the MIC of >64 μg/ml. This study was approved by the UT Health Northeast and Duke University institutional review boards.

**Variable-number tandem repeat typing.** Variable-number tandem repeat (VNTR) typing of the MAC isolates with MICs of >64 μg/ml and prior isolates with MICs of ≤32 μg/ml from the same patient were performed using previously described methods (8, 10, 11). Isolates of Mycobacterium chimaera were tested using Mycobacterium intracellulare primers (8).

**Quality control.** Quality control was performed using M. avium strain ATCC 700898 and incubation for 7 days as for the clinical isolates. The acceptable range of MICs was derived by using values ± one dilution from the modal value in a series of 34 test values. Additional quality control was provided using Pseudomonas aeruginosa strain ATCC 27853. After the established 18- to 24-h incubation period for bacteria, the acceptable MIC range for P. aeruginosa was 1 to 4 μg/ml, as previously defined by the CLSI (12).

**PCR restriction endonuclease analysis of the 16S rRNA gene.** A sequence of approximately 520 bp of the 16S rRNA gene that included bp position 1408 was selected for study and was amplified by PCR. Briefly, 25 μl of reaction mixture, which consisted of 12.5 μl of FailSafe PreMix I, 2 μmol of each primer, 0.625 μl of FailSafe PCR enzyme (Epicentre, Madison, WI), and 1 μl of template DNA was placed in a thermocycler for 35 cycles. Primer 261, corresponding to 16S RNA Escherichia coli positions 1520 to 1539 (5′-AAGGAGGTGATCCAGCCGCA-3′), and primer 297, corresponding to 16S RNA E. coli positions 1056 to 1075 (5′-TCCCTTG TGGCCCTGTGTGCACA-3′), were used (13). The amplicon size was approximately 520 and the readable sequence was 480 bp.

The restriction endonuclease Tsp45I (New England BioLabs, Ipswich, MA) failed to cut the 520-bp amplicon in the presence of the A1408G mutation but cut the wild-type sequence into two fragments of approximately 130 and 390 bp. PCR restriction endonuclease analysis (REA) was performed on isolates with amikacin MICs of ≥64 μg/ml. The use of this technique allows for the detection of a mixed population of isolates with and without the A1408G mutation.

**16S rRNA gene sequencing.** Isolates were subjected to sequencing of the 16S rRNA gene region, which was previously shown to confer resistance to amikacin in other mycobacteria (positions 1408, 1409, and 1411, Escherichia coli numbering system) (13).

**RESULTS**

Organisms. A total of 462 consecutive isolates from multiple states within the United States were tested. Isolates with initial and repeat amikacin MICs of >64 were reconfirmed as being of the MAC using a 16S multiplex PCR or commercially available DNA probes (AccuProbe; Hologic Gen-Probe, San Diego, CA). All seven of the repeat isolates were identified as species of the M. avium complex by ITS sequencing (8). These results demonstrated the presence of one isolate of M. avium, six isolates of M. intracellulare, and one isolate of M. chimaera.

An additional isolate from each of the seven patients with MAC isolates with initial and repeat MICs of >64 μg/ml from different time periods before and after the MIC of >64 μg/ml were identified and available for amikacin MIC and 16S rRNA gene analysis comparisons (Table 1).

**Susceptibility testing.** Almost one-half (48.9%) of the 462 consecutive clinical isolates had amikacin MICs of ≤8 μg/ml, and almost 90% (85.7%) had MICs of ≤≤16 μg/ml. The MIC50 was 16 μg/ml and MIC90 was 32 μg/ml. Only 1.7% of the isolates had amikacin MICs of 64 μg/ml, and only 2.1% of isolates had MICs of >64 μg/ml (Table 2). All eight isolates with amikacin MICs of 64 μg/ml had minimal growth (≥2-fold) in the 32-μg/ml well. On repeat testing, five of eight isolates had MICs of 32 μg/ml. Of the eight patients with MAC isolates of 64 μg/ml, clinical histories were inadequate to determine if there was a history of prior amikacin treatment.

Of the 10 isolates with initial MICs of >64 μg/ml, seven were reproducible on repeat testing (see Table 2). The amounts of growth in the 32-μg/ml and 64-μg/ml wells were equivalent to the control growth. The remaining three isolates had repeat MICs of 64 μg/ml (≥2-fold at 32 μg/ml).

**Patients.** Of the seven patients with MAC isolates with MICs of >64 μg/ml, on both initial and repeat testing, clinical histories were available for five. All five patients (Table 1, cases 1 to 5) had histories of prolonged (>6 months) prior drug therapy. Four patients were known to have received amikacin (three had inhaled and i.v. forms, one had an inhaled form only), and all were considered treatment failures. Not surprisingly, 5/7 isolates were also macrolide resistant, with clarithromycin MICs of >64 μg/ml. The case summary of one patient is listed below.

**Case summary.** Patient one was a 59-year-old female with nodular MAC lung disease. She was treated for 5 years with clarithromycin, ethambutol, and rifabutin with subsequent cessation of treatment for approximately 5 years when the isolate infecting the patient became macrolide resistant. Subsequently, the patient worsened clinically and showed marked worsening of her nodular disease on pulmonary computed tomography (CT) scan. Multiple sputum samples (6) over the past 3 years had 3+ to 4+ colony counts on 7H10 agar for MAC. The patient was started on three-times-weekly 300 mg rifabutin and 35 mg ethambutol/kg of body weight (see Fig. 1). The patient had never been on amikacin but had been on the latter two drugs at the same doses for the first 5 years. A daily regimen of 500 mg aerosolized amikacin was then added. The amikacin MIC was 8 μg/ml, and the isolate had a wild-type 16S rRNA gene at position 1408. At 6 months following initiation of the aerosolized amikacin regimen, the patient’s sputum MAC colony counts on 7H10 agar decreased to ≤50 colonies, and subsequently, the patient had her first negative acid-fast bacillus (AFB) culture in many years. However, at approximately 7 months after the initiation of amikacin therapy, the patient’s MAC colony counts on sputum cultures rose to 3+ to 4+ on 7H10 Middlebrook agar, and repeat amikacin MICs were >64 μg/ml. Follow-up amikacin MICs on additional isolates were also >64 μg/ml on both initial and repeat testing. Sequencing of the
### TABLE 1

<table>
<thead>
<tr>
<th>Case History</th>
<th>Culture</th>
<th>Identification</th>
<th>VNT5 type</th>
<th>Antibiotic MIC (µg/ml)</th>
<th>Exposure to antibiotic (days)</th>
<th>MIC Activity against M. avium Complex</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>WT</td>
<td>W/T</td>
<td>WT</td>
<td>64</td>
<td>&lt;6 (October 2012)</td>
<td>Improved then reported</td>
</tr>
<tr>
<td>2</td>
<td>WT</td>
<td>W/T</td>
<td>WT</td>
<td>64</td>
<td>&lt;6 (25 July 2007)</td>
<td>Improved then reported</td>
</tr>
<tr>
<td>3</td>
<td>WT</td>
<td>W/T</td>
<td>WT</td>
<td>64</td>
<td>&lt;6 (2 January 2012)</td>
<td>Improved then reported</td>
</tr>
<tr>
<td>4</td>
<td>WT</td>
<td>W/T</td>
<td>WT</td>
<td>64</td>
<td>&lt;6 (2 January 2012)</td>
<td>Improved then reported</td>
</tr>
<tr>
<td>5</td>
<td>WT</td>
<td>W/T</td>
<td>WT</td>
<td>64</td>
<td>&lt;6 (2 January 2012)</td>
<td>Improved then reported</td>
</tr>
<tr>
<td>6</td>
<td>WT</td>
<td>W/T</td>
<td>WT</td>
<td>64</td>
<td>&lt;6 (2 January 2012)</td>
<td>Improved then reported</td>
</tr>
<tr>
<td>7</td>
<td>WT</td>
<td>W/T</td>
<td>WT</td>
<td>64</td>
<td>&lt;6 (2 January 2012)</td>
<td>Improved then reported</td>
</tr>
</tbody>
</table>

**Notes:**
- Pre-Rx, pretreatment; Post-Rx, posttreatment.
- WT, wild-type
- Mut., A→G mutation at bp 1408.
- i.v., intravenous administration.
- CF, cystic fibrosis.
- CT, chest computed tomography.
- MIC, minimum inhibitory concentration.
TABLE 2 Initial broth microdilution amikacin MICs of 462 consecutive clinical isolates of M. avium complex a

<table>
<thead>
<tr>
<th>Initial amikacin MIC (µg/ml)</th>
<th>No. of isolates</th>
<th>Cumulative % of isolates</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1</td>
<td>7</td>
<td>1.5</td>
</tr>
<tr>
<td>2</td>
<td>18</td>
<td>5.4</td>
</tr>
<tr>
<td>4</td>
<td>57</td>
<td>17.7</td>
</tr>
<tr>
<td>8</td>
<td>144</td>
<td>48.9</td>
</tr>
<tr>
<td>16</td>
<td>171</td>
<td>85.9</td>
</tr>
<tr>
<td>64</td>
<td>46</td>
<td>95.9</td>
</tr>
<tr>
<td>&gt;64</td>
<td>9</td>
<td>97.8</td>
</tr>
</tbody>
</table>

a These data were determined with the CLSI-approved broth microdilution method (4). b MIC mode, 16 µg/ml; MIC90, 16 µg/ml; MIC50, 32 µg/ml.

16S rRNA gene sequencing. A 16S rRNA gene mutation of bp position 1408 in the two relapse isolates. Clinical treatment with amikacin related to the amikacin MICs and rrrn mutations is shown in Fig. 1.

Quality control. The amikacin MICs for the M. avium control strain ranged from 4 to 16 µg/ml. The strain M. avium ATCC 700898 was tested 34 times. The modald MIC was 8 µg/ml (28 values), with five values at 4 µg/ml and one value at 16 µg/ml. The MICs for P. aeruginosa ATCC 27853 were within the established CLSI acceptable range of 1 to 4 µg/ml (12).

VNTR typing. Pretreatment isolates with amikacin MICs of 8 µg/ml and posttherapy isolates of >64 µg/ml on initial and repeat testing in four patients (Table 1, cases 1, 2, 4, and 5), and one isolate obtained 4 months after an MIC of >64 µg/ml, which was 32 µg/ml, underwent VNTR typing. All paired isolates belonged to the same species, and all had the same VNTR type, excluding the possibility of infection with a new recent isolate with an MIC of >64 µg/ml or specimen contamination. Case 4 had two VNTR genotypes on initial testing (Table 1).

PRA of the 16S rRNA gene. A total of 40 patient isolates with amikacin MICs of ≤32 µg/ml underwent PRA. All exhibited a wild-type bp at position 1408. Of the eight isolates with initial amikacin MICs of 64 µg/ml (all with ≥ growth at 32 µg/ml), all exhibited a wild-type bp at position 1408. Of the 10 isolates with initial amikacin MICs of >64 µg/ml, seven isolates from six patients had the same MIC on repeat testing. All seven of these isolates exhibited a mutation at 16S rRNA position 1408. The three isolates with a repeat MIC of ≤64 µg/ml were also wild type.

16S rRNA gene sequencing. A 16S rRNA gene mutation of bp A1408G was observed in all seven of the isolates with a mutation pattern on PRA testing. Upon sequencing the 530-bp region, no other mutations were observed. The sequencing of seven isolates with MICs of 32 µg/ml and 64 µg/ml, and those with >64 µg/ml on only two of the MIC determinations also showed a wild-type 530-bp region.

DISCUSSION

This study demonstrates that 96.2% of the clinical MAC isolates submitted for susceptibility testing have MICs of ≤32 µg/ml using the CLSI susceptibility testing method (4).

The amikacin MIC values are consistent within the achievable serum and inhaled levels and with the clinical response to MAC that is seen when amikacin is used, especially in patients with cavitary disease or macrolide resistance (2). Prolonged exposure to amikacin was present in isolates with initial and repeat MICs of >64 µg/ml, which correlated with the development of a 16S rRNA gene A→G mutation at position 1408. This was clearly demonstrated in case 1 (Fig. 1).

The amikacin MIC results reported in each well for each isolate with MICs of ≥64 µg/ml were compared to the control growth in each panel. There are several possible explanations for the minimal amounts of growth seen at 32 µg/ml with isolates with amikacin MICs of 64 µg/ml (interpreted as ≥ growth). These include the presence of an aminoglycoside-modifying enzyme that is weakly inducible, such as the erm gene that is seen in rapidly growing mycobacteria (14). Other possibilities are related to the presence of inoculum effects in drugs, such as ethambutol or sulfonamides, which need carefully controlled inocula to prevent trailing endpoints (3), or that the prior concentration with growth (i.e., 32 µg/ml) is very close to the real MIC, which still might be within achievable drug levels (especially for inhaled amikacin) (13, 15, 16).

The ≥ growth interpretation at 32 µg/ml might also be attributed to reader interpretation. Multiple individuals read the amikacin MICs over the course of the study. A comparison of readings performed by readers with little experience (≤2 years) in reading MAC susceptibilities compared to readers with considerable experience (>5 years) showed that the wells recorded as “≥” by the less-experienced reader would have been recorded as negative by the more experienced reader (B. Brown-Elliott, unpublished data). This was supported by the finding that most of the isolates with initial amikacin MICs of 64 µg/ml had MICs of 32 µg/ml on repeat testing (5/8). Thus, just as CLSI guidelines currently recommend repeating amikacin MIC determinations for isolates of M. abscessus with MICs of ≥64 µg/ml, it is important to confirm amikacin MICs of ≥64 µg/ml in isolates of the MAC by either repeating the MIC or by sending the isolates to a qualified refer-
ence laboratory with specific experience in MAC susceptibility testing (4).

The assertion that an elevated amikacin MIC should be deemed amikacin resistant (with implications for subsequent treatment) may seem to contradict earlier works that found no association between aminoglycoside (streptomycin in this study) MICs and clinical outcomes in MAC pulmonary disease (17–19). However, the differences between the present findings and the earlier works are readily explicable. The patients in the prior studies had not been previously treated for MAC, and a relatively small number of isolates had streptomycin MICs of ≥64 μg/ml. If the resistance cutoff for streptomycin is similar to that for amikacin (which might be expected given their similar pharmacokinetics and mechanisms of action), a very small number of patients in these studies would be in the resistant range, providing limited power to discern differences. A variation in the MICs within a susceptible range would not necessarily be expected to be associated with differences in clinical outcomes. Furthermore, all patients in these studies were treated with multiple drugs, so susceptibility or resistance to a single drug might have had a limited impact on outcomes. Furthermore, heterogeneity in the severity and extent of clinical disease reduces the power to detect significant associations between antimicrobial susceptibility and treatment outcomes. Larger prospective studies will be needed to address these questions.

Additional mutations related to amikacin resistance other than rrm A1408G have been demonstrated in other mycobacterial species (16). It is possible that MAC isolates with amikacin MICs of ≥64 μg/ml may harbor a mutation other than the position 1408 mutation, and this question remains under investigation.

We recommend that isolates of the MAC be routinely tested against amikacin by broth microdilution assay. We further propose that the amikacin breakpoints for M. abscessus susceptibility be adopted for isolates of the MAC: MICs of ≥16 μg/ml would be considered susceptible, 32 μg/ml, intermediate, and ≥64 μg/ml, resistant. These values may allow for better usage of amikacin with either i.v. or inhaled administration, and they highlight the finding that MICs of >64 μg/ml on initial and repeat testing may develop with prolonged drug therapy as a consequence of a ribosomal mutation that is not seen in isolates with lower amikacin MICs. There are no data at present to suggest that the breakpoints for inhaled amikacin for both M. abscessus and MAC may be different than those approved or proposed for intravenous administration. There currently are no CLSI breakpoints for two other inhaled antibiotics (tobramycin and aztreonam) that are FDA approved for the treatment of P. aeruginosa in patients with cystic fibrosis. The single case report (case 1) and other isolates from patients with available treatment histories suggest that higher concentrations of inhaled amikacin are not effective in the presence of the ribosomal mutation described here. The efficacy of inhaled therapy for isolates with MICs of 64 μg/ml will need evaluation, as their response for therapy is not known.

Financial support for this study was provided by in-house funding and a grant from the Amron G. Carter Foundation.

REFERENCES


15. Brown-Elliott BA, Nash KA, Wallace RJ, Jr. 2012. Antimicrobial suscep-


ERRATUM

In Vitro Activity of Amikacin against Isolates of *Mycobacterium avium* Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates


Mycobacteria/Nocardia Research Laboratory and the Department of Microbiology, UT Health Northeast (formerly The University of Texas Health Science Center at Tyler), Tyler, Texas, USA; Department of Medicine, UT Health Northeast, Tyler, Texas, USA; Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA; Duke University Medical Center, Durham, North Carolina, USA; Saskatchewan Disease Control Laboratory, Regina, Saskatchewan, Canada


Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JCM.00224-14